AbbVie (NYSE:ABBV) Issues Quarterly Earnings Results, Misses Expectations By $0.82 EPS

AbbVie (NYSE:ABBV) announced its earnings results on Friday. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82), RTT News reports. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. During the same quarter in the prior year, the business earned $2.79 EPS. AbbVie updated its FY 2025 guidance to 12.120-12.320 EPS.

AbbVie Trading Up 5.2 %

ABBV stock traded up $9.19 during mid-day trading on Friday, reaching $184.84. 6,787,204 shares of the stock traded hands, compared to its average volume of 5,945,484. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie has a one year low of $153.58 and a one year high of $207.32. The stock has a market capitalization of $326.63 billion, a PE ratio of 64.14, a PEG ratio of 1.77 and a beta of 0.58. The business has a 50-day moving average price of $176.43 and a two-hundred day moving average price of $184.84.

Analyst Ratings Changes

ABBV has been the subject of a number of recent analyst reports. UBS Group upped their price target on shares of AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Barclays upped their price target on shares of AbbVie from $200.00 to $212.00 and gave the stock an “overweight” rating in a research report on Monday, October 7th. Piper Sandler upped their price target on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Truist Financial dropped their price target on shares of AbbVie from $215.00 to $211.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company upped their price target on shares of AbbVie to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $205.00.

Insider Transactions at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.